Quinnmeincke6677
On multivariable analysis, low SMI remained an independent risk factor with an odds ratio of 4.74, 95% confidence interval 1.22-18.36 (p = 0.02).
Low SMI was found to be an independent risk factor for 30-day mortality in patients submitted to colorectal surgery with a primary anastomosis, whether for benign or malignant diagnosis. Crenolanib VFA was not associated with 30-day mortality.
Low SMI was found to be an independent risk factor for 30-day mortality in patients submitted to colorectal surgery with a primary anastomosis, whether for benign or malignant diagnosis. VFA was not associated with 30-day mortality.Locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC) of the skin is a rare entity and with a poor prognosis. Although less than 5% of patients with squamous carcinoma develop metastases or relapses locally after surgical removal, cSCC is difficult to treat. It tends to develop especially in elderly, frail or patients with important comorbidities and therefore not suitable for receiving aggressive treatments. Traditionally, platinum-based therapy has been considered a conventional option, but not feasible in elderly patients. The high number of advanced cSCC mutations constitutes the rationale for a systemic immunotherapy approach that can represent a turning point for these patients. Furthermore, it is necessary that more professional figures (dermatologist, oncologist, surgeon, radiotherapist, geriatrician) work in a multidisciplinary environment so that these patients can be better managed during their care path.
The aim of this study was to assess compliance with guidelines recommendations in the follow-up of patients with breast cancer. In this setting of patients we analyzed the appropriateness of the imaging exams recommended by different specialists in the management of follow-up.
From January 2019 to December 2019 we analyzed the clinical data and the results of the imaging exams of 146 asymptomatic patients followed for follow-up in different regional radiotherapy centers. A logistic regression analysis was performed taking into account the advanced pathological stage, the absence of surgical staging of the lymph nodes, the dubious results from previous basic imaging tests, correlating them to the excessive use of advanced imaging. The association was expressed in terms of odds ratio (OR) together with their 95% confidence intervals (CI).
For 96% of patients, a frequent prescription of at least one basic imaging exam (complete abdomen ETG and chest X-ray 2p) was observed in contrast to the guidelines. A finding of a large number of bone scans suggested their use as routine surveillance A positive correlation with advanced imaging (OR <1) was seen in patients with borderline basic imaging.
Follow-up with intensive imaging is poorly effective both for the early diagnosis of relapses and for any remote localizations.
Follow-up with intensive imaging is poorly effective both for the early diagnosis of relapses and for any remote localizations.
The adherence to recognized guidelines and the constant monitoring of performance throughout quality indicators (QIs) are strategic tools to improve the quality of care. The study is aimed to assess the effect of the EUSOMA (European Society of Breast Cancer Specialists) certification process on the quality of breast cancer care of an EUSOMA certified Breast Unit (BU) of Northern Italy.
Seventeen mandatory and recommended EUSOMA QIs, based on 594, were analysed for the years 2015-2018. Univariate logistic regression models were performed to compare QIs performance in the years before and after obtaining the EUSOMA certification (2015-6 vs. 2017-8).
Compared to the years 2015-6, the second period of BU activity showed a higher number of QIs achieving both the minimum standard (15 vs. 11) and the 100% of completeness (6 vs. 1). There was a significant improvement of the two QIs evaluating the proportion of Ductal Carcinoma in situ receiving just an operation (from 76% to 95.2%; p=0.033) and the completeness of the prognostic characterisation of invasive cancers (from 94.6% to 99.5%; p=0.022). Conversely, the QI related to the endocrine-sensitive invasive carcinoma receiving adjuvant hormonal therapy dropped from 92.1% to 85.9% (p=0.042) and was significantly lower for patients over 74 compared to those aged ≤54 (73.8% vs. 94.7%; p<0.0001 Fisher's exact test).
The EUSOMA certification process enhanced the clinical practice, promoting a tailored-patient primary systemic or adjuvant therapy and avoiding unnecessary invasive surgical and local-regional treatments.
The EUSOMA certification process enhanced the clinical practice, promoting a tailored-patient primary systemic or adjuvant therapy and avoiding unnecessary invasive surgical and local-regional treatments.
Measuring quality of life and factors influencing it such as pain and anxiety is a major part of the overall assessment of cancer patients. There are different clinical settings aimed at satisfying the needs of this patients. The purpose of this study was to assess the different perceptions of quality of life in cancer patients in integrated home oncological care (ADI) and hospice.
We invited to participate all subjects suffering from oncological pathology followed with home care activities at ANT, ODO Bat-Bari Nord and inpatients at the hospice "Mons. Aurelio Marena" in Bitonto (BA) from 15/10/2019 to 15/07/2020. During the 4 collection phases, BPI, STAI-Y 1-2, EORTC were administered.
80 subjects were consecutively enrolled, divided in the same proportion in ADI and hospice. At the end of the study the pain intensity in subjects in ADI was significantly lower than baseline (p=0.02) and the level shown by subjects hospitalized in hospice (p=0.01). No differences in anxiety were found between the settin It is desirable to investigate the prognostic value of the quality of life perceived by patients.The development of biological drugs, which began in the 1980s, has revolutionized the treatment of numerous oncological diseases and severely disabling autoimmune diseases, with widely demonstrated evidence of benefit. Today, biological drugs represent an important and continuously developing category and are used both as a support therapy in onco-hematology and as molecules with their own therapeutic activity, such as monoclonal antibodies. Among these, bevacizumab represents a drug of relevant clinical value, used as antiangiogenic therapy in numerous cancers, in particular colorectal and ovarian cancers. The expiry of the patent period of monoclonal antibodies, including bevacizumab, has opened up to the development of biosimilar drugs, represented by structurally similar molecules with pharmacokinetic, pharmacodynamic and clinical characteristics equivalent to a biological drug already present in clinical use (originator biologic). The development process of these drugs is contained in the guidelines of the major regulatory bodies (FDA/EMA) and is faster than that provided for the originator biologic.
